Kassi Filkins

New five-year data reveals SYFOVRE significantly delays geographic atrophy progression, enhancing understanding of age-related macular degeneration treatment.

Catch up on this week's highlights in retina.

Catch up on this week's highlights in retina.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

Innovative retinal therapies are advancing through FDA trials, promising breakthroughs in treating various retinal diseases.

Catch up on this week's highlights in retina.

Catch up on this week's highlights in retina.

Catch up on this week's highlights in retina.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Catch up on this week's highlights in retina.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Catch up on this week's highlights in retina.

The newly approved technology delivers low-dose microcurrents through closed eyelids to stimulate retinal cells.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Luxa Biotechnology reveals promising phase 1/2a trial results for RPESC-RPE therapy, showing safety and potential vision restoration in patients with dry AMD.

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Catch up on this week's highlights in retina.

Kodiak Sciences reveals promising APEX study results for KSI-101, showing significant vision improvement in macular edema patients.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

Catch up on this week's highlights in retina.

Sanofi's gene therapy SAR402663 receives FDA fast track designation, targeting neovascular age-related macular degeneration with positive clinical trial data.

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared with nonpregnant controls.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.